Thrombosis with low-estrogen oral contraceptives

Area of Science:

• Pharmacovigilance
• Thrombosis Epidemiology
• Reproductive Health

Background:

• Oral contraceptives (OCs) are widely used for birth control.
• Previous studies have suggested a link between OCs and thrombotic events.
• Understanding the precise risks associated with different formulations and patient groups is crucial.

Purpose of the Study:

• To investigate the relationship between oral contraception use and thrombosis.
• To assess the risk in idiopathic cases versus other thrombotic cases.
• To evaluate the influence of estrogen dosage and identify potential biases.

Main Methods:

• Retrospective study design.
• Inclusion of 104 idiopathic cases, 357 other thrombotic cases, and 1302 matched controls.
• Accurate assessment of oral contraceptive use histories.

Main Results:

• Users of oral contraception had a 1.9 times higher risk of thrombosis overall.
• Idiopathic cases showed a significantly higher relative risk of 7.2 times compared to non-users.
• Higher estrogen doses (≥100 µg) were associated with increased risk; gallbladder surgery risk doubled for users.

Conclusions:

• A definite risk of thrombosis is associated with oral contraceptive use, even with current low-estrogen formulations.
• Selective prescription may explain lower observed risks in non-idiopathic cases.
• The study found no significant biases and confirmed the accuracy of contraceptive use histories.